Develops nanotherapeutics for cancer treatment.
Dec 2025Revenue €32.6M/yrExpenses €43.4M/yr
No trendCash runway ≈ 1.6 years from Dec 2025
Figures by year
When will Nanobiotix be profitable?
Its figures don’t show a steady enough trend to project a date. In the 12 months to Dec 2025, revenue was €32.6M and expenses €43.4M.
| Fiscal year to | Revenue | Expenses | Operating profit |
|---|---|---|---|
| Dec 2025 | €32.6M | €43.4M | −€10.8M |
| Dec 2024 | −€7.19M | €61.2M | −€68.4M |
| Dec 2023 | €36.2M | €63.0M | −€26.8M |
| Dec 2022 | €4.78M | €51.5M | −€46.7M |
| Dec 2021 | €2.65M | €55.2M | −€52.6M |
| Dec 2020 | €2.51M | €38.9M | −€36.4M |
| Dec 2019 | €2.54M | €49.3M | −€46.8M |
| Dec 2018 | €3.48M | €33.5M | −€30.1M |
When the cash runs out, on the chart. A red line at the date the company’s cash would run out at its latest burn, so you can see whether it gets to break-even first. Part of a subscription.